Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

This can seriously affect day-to-day functioning. Type 1 narcolepsy patients have cataplexy, a transient sudden loss of voluntary muscle control brought on by a strong emotional trigger such as ...

Cataplexy is the least common symptom of these, and many people with narcolepsy never experience it. Narcolepsy with cataplexy is called narcolepsy type 1, while narcolepsy without cataplexy is ...

In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control. When patients experience intense emotion, either positive or ...

extended-release oral suspension to include treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Previously the treatment had only ...

Mazindol ER is under clinical development by NLS Pharmaceutics and currently in Phase II for Type 2 Narcolepsy (Narcolepsy without Cataplexy). According to GlobalData, Phase II drugs for Type 2 ...

In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and at least twice placebo) for WAKIX were ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

It was granted orphan drug designation for the treatment of narcolepsy in 2010, and breakthrough therapy designation for the treatment of cataplexy in 2018. WAKIX is a selective histamine 3 (H₃ ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline make it a strong buy for 2025.

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. Avadel Pharmaceuticals PLC (AVDL ...